🎉 M&A multiples are live!
Check it out!

SCYNEXIS Valuation Multiples

Discover revenue and EBITDA valuation multiples for SCYNEXIS and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

SCYNEXIS Overview

About SCYNEXIS

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.


Founded

1999

HQ

United States of America
Employees

28

Website

scynexis.com

Financials

LTM Revenue $9.7M

LTM EBITDA n/a

EV

-$4.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

SCYNEXIS Financials

SCYNEXIS has a last 12-month revenue of $9.7M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, SCYNEXIS achieved revenue of $3.7M and an EBITDA of -$20.3M.

SCYNEXIS expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See SCYNEXIS valuation multiples based on analyst estimates

SCYNEXIS P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $140M $3.7M XXX XXX XXX
Gross Profit $4.5M $125M XXX XXX XXX
Gross Margin 3% 3324% XXX XXX XXX
EBITDA $70.9M -$20.3M XXX XXX XXX
EBITDA Margin 51% -542% XXX XXX XXX
Net Profit -$62.8M $67.0M XXX XXX XXX
Net Margin -45% 1790% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

SCYNEXIS Stock Performance

As of April 15, 2025, SCYNEXIS's stock price is $1.

SCYNEXIS has current market cap of $38.5M, and EV of -$4.6M.

See SCYNEXIS trading valuation data

SCYNEXIS Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$4.6M $38.5M XXX XXX XXX XXX $-0.40

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

SCYNEXIS Valuation Multiples

As of April 15, 2025, SCYNEXIS has market cap of $38.5M and EV of -$4.6M.

SCYNEXIS's trades at -0.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate SCYNEXIS's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for SCYNEXIS and 10K+ public comps

SCYNEXIS Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$4.6M XXX XXX XXX
EV/Revenue -1.2x XXX XXX XXX
EV/EBITDA 0.2x XXX XXX XXX
P/E -1.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get SCYNEXIS Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

SCYNEXIS Valuation Multiples

SCYNEXIS's NTM/LTM revenue growth is 322%

SCYNEXIS's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.5M for the same period.

Over next 12 months, SCYNEXIS's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate SCYNEXIS's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for SCYNEXIS and other 10K+ public comps

SCYNEXIS Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -97% XXX XXX XXX XXX
EBITDA Margin -542% XXX XXX XXX XXX
EBITDA Growth -129% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -220% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 705% XXX XXX XXX XXX
Opex to Revenue 1091% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

SCYNEXIS Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

SCYNEXIS M&A and Investment Activity

SCYNEXIS acquired  XXX companies to date.

Last acquisition by SCYNEXIS was  XXXXXXXX, XXXXX XXXXX XXXXXX . SCYNEXIS acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by SCYNEXIS

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About SCYNEXIS

When was SCYNEXIS founded? SCYNEXIS was founded in 1999.
Where is SCYNEXIS headquartered? SCYNEXIS is headquartered in United States of America.
How many employees does SCYNEXIS have? As of today, SCYNEXIS has 28 employees.
Who is the CEO of SCYNEXIS? SCYNEXIS's CEO is Dr. David Angulo, M.D..
Is SCYNEXIS publicy listed? Yes, SCYNEXIS is a public company listed on NAS.
What is the stock symbol of SCYNEXIS? SCYNEXIS trades under SCYX ticker.
When did SCYNEXIS go public? SCYNEXIS went public in 2014.
Who are competitors of SCYNEXIS? Similar companies to SCYNEXIS include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of SCYNEXIS? SCYNEXIS's current market cap is $38.5M
What is the current revenue of SCYNEXIS? SCYNEXIS's last 12-month revenue is $9.7M.
What is the current EV/Revenue multiple of SCYNEXIS? Current revenue multiple of SCYNEXIS is -0.5x.
What is the current revenue growth of SCYNEXIS? SCYNEXIS revenue growth between 2023 and 2024 was -97%.
Is SCYNEXIS profitable? Yes, SCYNEXIS is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.